Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Thoracic Malignancies
•
Medical Oncology
•
NCI-CCC Tumor Board Question
•
Non-small cell lung cancer
•
Ohio State University
•
NCI-CCC Thoracic Tumor Board Question
How would you treat oligometastatic NSCLC (brain and bone) with Non-V600E BRAF mutations?
SRS done to the single brain met, PD-L1 5%, BRAF G469A mutation
Answer from: Medical Oncologist at Academic Institution
I would treat with chemo-pembro. Down the road, MEK inhibitors is a choice.
Sign In
or
Register
to read more
8093
Related Questions
How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
How do you talk with your patients regarding radiographic expectations on surveillance CT after lung SBRT?
How would you treat a patient with metastatic NSCLC, adenocarcinoma subtype with BRAF V600K mutation, PD-L1 >50% with progression on 1st line chemo-immunotherapy?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
What are your top takeaways in thoracic cancers from ESMO 2025?
How do you prioritize treatment in a lung cancer patient who has HER2 IHC3+ along with other actionable mutations that have tumor-specific drugs available?